Italy Diabetes Drugs Market Size
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 1.12 Billion |
| Market Size (2029) | USD 1.31 Billion |
| CAGR (2024 - 2029) | 3.00 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Italy Diabetes Drugs Market Analysis
The Italy Diabetes Drugs Market size is estimated at USD 1.12 billion in 2024, and is expected to reach USD 1.31 billion by 2029, growing at a CAGR of 3% during the forecast period (2024-2029).
People with diabetes have more chances to get into serious complications rather than normal people. The manufacturers of diabetes drugs have taken care during COVID-19 to deliver the medications to diabetes patients with the help of local governments. Novo Nordisk stated on their website that 'Since the start of COVID-19, our commitment to patients, our employees and the communities where we operate has remained unchanged, we continue to supply our medicines and devices to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses as they work to defeat COVID-19.'
The World Health Assembly agreed on a Resolution on strengthening the prevention and control of diabetes. It recommends action in areas including increasing access to insulin; promoting convergence and harmonization of regulatory requirements for insulin and other medicines and health products for the treatment of diabetes; and assessing the feasibility and potential value of establishing a web-based tool to share information relevant to the transparency of markets for diabetes medicines and health products.
Italy witnessed an alarming increase in the prevalence of diabetes in recent years. Patients with diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as oral anti-diabetic medication or ingestion of additional carbohydrates by monitoring their blood glucose levels. The rate of newly diagnosed Type 1 and Type 2 diabetes cases is seen to increase, mainly due to obesity, unhealthy diet, and physical inactivity. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure are indications of the increasing usage of diabetic drugs.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Italy Diabetes Drugs Market Trends
Oral anti-diabetic drugs are expected to register highest growth rate in the Italy Diabetes Drugs Market over the forecast period
The Oral Anti-Diabetic Drugs market is expected to register the highest CAGR of about 3.5% in the Italy Diabetes Drugs Market over the forecast period.
Oral Anti-Diabetic Drugs are available internationally and are recommended for use when escalation of treatment for type 2 diabetes is required along with lifestyle management. Oral agents are typically the first medications used in treating type 2 diabetes due to their wide range of efficacy, safety, and mechanisms of action.
Anti-diabetic drugs help diabetes patients control their condition and lower the risk of diabetes complications. People with diabetes may need to take anti-diabetic drugs for their whole lives to control their blood glucose levels and avoid hypoglycemia and hyperglycemia. Oral anti-diabetic agents present the advantages of easier management and lower cost. So they became an attractive alternative to insulin with better acceptance, which enhances adherence to the treatment.
The Italy National Healthcare Service (NHS) is ensuring universal coverage for all citizens. People living with diabetes can access all the medicines, devices, and medical services they need with no out-of-pocket expenditure. Overall, Italy includes a well-developed system of diabetes care, with numerous diabetes centers throughout the country and treatment free at the point of delivery. The Italy health system is highly decentralized, with most administrative and organizational powers held by the Regions. The National Diabetes Plan defines priorities and provides guidelines to improve the quality of diabetes care with a patient-centered focus.
Owing to the above factors, the market will likely continue to grow.
Glucagon-like Peptide-1 Receptor Agonist segment holds the highest market share in the Italy Diabetes Drugs Market in the current year
Glucagon-like Peptide-1 Receptor Agonist segment holds the highest market share of about 22% in the Italy Diabetes Drugs Market in the current year.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of medications used for treating type 2 diabetes, and some drugs are also approved for obesity. One of the benefits of this class of drugs over older insulin secretagogues, such as sulfonylureas or meglitinides, is that they include a lower risk of causing hypoglycemia. Besides being important glucose-lowering agents, GLP-1RAs contain significant anti-inflammatory and pulmonary protective effects and a favorable impact on gut microbes' composition.
Italian law regulates the clinical care of people with diabetes and creates a framework involving medical organizations, prevention programs, personnel training, and legal protection. The National Health Program is structured in essential levels of assistance that can be defined differently in the various regions. The National Health Program is structured in LEAs (essential levels of assistance). LEAs define all the medical assistance modalities offered by the INHS to citizens, with or without partial contributions, based on a patient's income.
Diabetes is a significant health problem and one of the tremendous challenges for healthcare systems all over Italy. The disease's growing incidence, prevalence, and progressive nature encouraged the development of new drugs to provide additional treatment options for diabetic patients. The roll-out of many new products, increasing international research collaborations in technology advancement, and increasing awareness about diabetes among the people are some of the market opportunities for the players in the Italy diabetes drugs market.
Italy Diabetes Drugs Industry Overview
The Italy Diabetes Drugs Market is moderately fragmented, with major manufacturers, namely Eli Lilly, Sanofi, Novo Nordisk, AstraZeneca, and other generic players, holding a presence in the region. A major share of the market is held by manufacturers concomitant with strategy-based M&A operations and constantly entering the market to generate new revenue streams and boost existing ones.
Italy Diabetes Drugs Market Leaders
-
Novo Nordisk A/S
-
AstraZeneca
-
Boehringer Ingelheim
-
Sanofi Aventis
-
Eli Lilly and Company
*Disclaimer: Major Players sorted in no particular order
Italy Diabetes Drugs Market News
- December 2023: Boehringer Ingelheim and Eli Lilly have received approval from the European Commission (EC) for Jardiance® (empagliflozin) 10mg and 25mg tablets in children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus (T2D) as an adjunct to diet and exercise
- March 2022: Eli Lilly and Boehringer Ingelheim gained approval for heart failure treatment from the EU for sodium-glucose co-transporter-2-inhibitor, Jardiance (empagliflozin).
- February 2022: Bayer was granted marketing authorization in the European Union for Kerendia (finerenone) to treat the loss of kidney function, or chronic kidney disease, in adults with type 2 diabetes. It also aims to reduce the risk of kidney failure, heart attack, and death due to heart conditions.
Italy Diabetes Drugs Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 Insulins
- 5.1.1 Basal or Long Acting Insulins
- 5.1.1.1 Lantus (Insulin Glargine)
- 5.1.1.2 Levemir (Insulin Detemir)
- 5.1.1.3 Toujeo (Insulin Glargine)
- 5.1.1.4 Tresiba (Insulin Degludec)
- 5.1.1.5 Basaglar (Insulin Glargine)
- 5.1.2 Bolus or Fast Acting Insulins
- 5.1.2.1 NovoRapid/Novolog (Insulin Aspart)
- 5.1.2.2 Humalog (Insulin Lispro)
- 5.1.2.3 Apidra (Insulin Glulisine)
- 5.1.3 Traditional Human Insulins
- 5.1.3.1 Novolin/Actrapid/Insulatard
- 5.1.3.2 Humulin
- 5.1.3.3 Insuman
- 5.1.4 Biosimilar Insulins
- 5.1.4.1 Insulin Glargine Biosimilars
- 5.1.4.2 Human Insulin Biosimilars
-
5.2 Oral Anti-diabetic drugs
- 5.2.1 Biguanides
- 5.2.1.1 Metformin
- 5.2.2 Alpha-Glucosidase Inhibitors
- 5.2.2.1 Alpha-Glucosidase Inhibitors
- 5.2.3 Dopamine D2 receptor agonist
- 5.2.3.1 Bromocriptin
- 5.2.4 SGLT-2 inhibitors
- 5.2.4.1 Invokana (Canagliflozin)
- 5.2.4.2 Jardiance (Empagliflozin)
- 5.2.4.3 Farxiga/Forxiga (Dapagliflozin)
- 5.2.4.4 Suglat (Ipragliflozin)
- 5.2.5 DPP-4 inhibitors
- 5.2.5.1 Onglyza (Saxagliptin)
- 5.2.5.2 Tradjenta (Linagliptin)
- 5.2.5.3 Vipidia/Nesina(Alogliptin)
- 5.2.5.4 Galvus (Vildagliptin)
- 5.2.6 Sulfonylureas
- 5.2.6.1 Sulfonylureas
- 5.2.7 Meglitinides
- 5.2.7.1 Meglitinides
-
5.3 Non-Insulin Injectable drugs
- 5.3.1 GLP-1 receptor agonists
- 5.3.1.1 Victoza (Liraglutide)
- 5.3.1.2 Byetta (Exenatide)
- 5.3.1.3 Bydureon (Exenatide)
- 5.3.1.4 Trulicity (Dulaglutide)
- 5.3.1.5 Lyxumia (Lixisenatide)
- 5.3.2 Amylin Analogue
- 5.3.2.1 Symlin (Pramlintide)
-
5.4 Combination drugs
- 5.4.1 Insulin combinations
- 5.4.1.1 NovoMix (Biphasic Insulin Aspart)
- 5.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
- 5.4.1.3 Xultophy (Insulin Degludec and Liraglutide)
- 5.4.2 Oral Combinations
- 5.4.2.1 Janumet (Sitagliptin and Metformin)
6. MARKET INDICATORS
- 6.1 Type-1 Diabetic Population
- 6.2 Type-2 Diabetic Population
7. COMPETITIVE LANDSCAPE
-
7.1 COMPANY PROFILES
- 7.1.1 Novo Nordisk A/S
- 7.1.2 Takeda
- 7.1.3 Pfizer
- 7.1.4 Eli Lilly
- 7.1.5 Janssen Pharmaceuticals
- 7.1.6 Astellas
- 7.1.7 Boehringer Ingelheim
- 7.1.8 Merck and Co.
- 7.1.9 AstraZeneca
- 7.1.10 Bristol Myers Squibb
- 7.1.11 Novartis
- 7.1.12 Sanofi Aventis
- *List Not Exhaustive
-
7.2 COMPANY SHARE ANALYSIS
- 7.2.1 Novo Nordisk A/S
- 7.2.2 Sanofi Aventis
- 7.2.3 Eli Lilly
- 7.2.4 Merck and Co.
- 7.2.5 Others
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityItaly Diabetes Drugs Industry Segmentation
Diabetes Drugs are used to manage diabetes mellitus by lowering the glucose level in the blood. The Italy Diabetes Drugs Market is segmented into insulin drugs, oral anti-diabetic drugs, and combination drugs. The report offers the value (in USD) and volume (in units) for the above segments.
| Insulins | Basal or Long Acting Insulins | Lantus (Insulin Glargine) |
| Levemir (Insulin Detemir) | ||
| Toujeo (Insulin Glargine) | ||
| Tresiba (Insulin Degludec) | ||
| Basaglar (Insulin Glargine) | ||
| Insulins | Bolus or Fast Acting Insulins | NovoRapid/Novolog (Insulin Aspart) |
| Humalog (Insulin Lispro) | ||
| Apidra (Insulin Glulisine) | ||
| Insulins | Traditional Human Insulins | Novolin/Actrapid/Insulatard |
| Humulin | ||
| Insuman | ||
| Insulins | Biosimilar Insulins | Insulin Glargine Biosimilars |
| Human Insulin Biosimilars | ||
| Oral Anti-diabetic drugs | Biguanides | Metformin |
| Oral Anti-diabetic drugs | Alpha-Glucosidase Inhibitors | Alpha-Glucosidase Inhibitors |
| Oral Anti-diabetic drugs | Dopamine D2 receptor agonist | Bromocriptin |
| Oral Anti-diabetic drugs | SGLT-2 inhibitors | Invokana (Canagliflozin) |
| Jardiance (Empagliflozin) | ||
| Farxiga/Forxiga (Dapagliflozin) | ||
| Suglat (Ipragliflozin) | ||
| Oral Anti-diabetic drugs | DPP-4 inhibitors | Onglyza (Saxagliptin) |
| Tradjenta (Linagliptin) | ||
| Vipidia/Nesina(Alogliptin) | ||
| Galvus (Vildagliptin) | ||
| Oral Anti-diabetic drugs | Sulfonylureas | Sulfonylureas |
| Oral Anti-diabetic drugs | Meglitinides | Meglitinides |
| Non-Insulin Injectable drugs | GLP-1 receptor agonists | Victoza (Liraglutide) |
| Byetta (Exenatide) | ||
| Bydureon (Exenatide) | ||
| Trulicity (Dulaglutide) | ||
| Lyxumia (Lixisenatide) | ||
| Non-Insulin Injectable drugs | Amylin Analogue | Symlin (Pramlintide) |
| Combination drugs | Insulin combinations | NovoMix (Biphasic Insulin Aspart) |
| Ryzodeg (Insulin Degludec and Insulin Aspart) | ||
| Xultophy (Insulin Degludec and Liraglutide) | ||
| Combination drugs | Oral Combinations | Janumet (Sitagliptin and Metformin) |
Italy Diabetes Drugs Market Research FAQs
How big is the Italy Diabetes Drugs Market?
The Italy Diabetes Drugs Market size is expected to reach USD 1.12 billion in 2024 and grow at a CAGR of 3% to reach USD 1.31 billion by 2029.
What is the current Italy Diabetes Drugs Market size?
In 2024, the Italy Diabetes Drugs Market size is expected to reach USD 1.12 billion.
Who are the key players in Italy Diabetes Drugs Market?
Novo Nordisk A/S, AstraZeneca, Boehringer Ingelheim, Sanofi Aventis and Eli Lilly and Company are the major companies operating in the Italy Diabetes Drugs Market.
What years does this Italy Diabetes Drugs Market cover, and what was the market size in 2023?
In 2023, the Italy Diabetes Drugs Market size was estimated at USD 1.09 billion. The report covers the Italy Diabetes Drugs Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Italy Diabetes Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Italy Diabetes Drugs Industry Report
Statistics for the 2024 Italy Diabetes Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Italy Diabetes Drugs analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
